Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents

Ekaterina Stepanova, Susannah Dowling, Molly Phelps, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD. Though not FDA-approved, methylphenidate and guanfacine are effective for the management of hyperactivity in children with ASD. Selective serotonin reuptake inhibitors are often used in clinical practice to target anxiety and compulsions; however, there is little evidence to support its use in this population. There is a great need for further research on the safety and efficacy of existing psychotropic medications in youth with ASD, as well as the development of new treatment modalities for the core and associated behavioral symptoms.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalDialogues in Clinical Neuroscience
Volume19
Issue number4
StatePublished - Dec 1 2017

Fingerprint

Behavioral Symptoms
Drug Therapy
United States Food and Drug Administration
Guanfacine
Methylphenidate
Risperidone
Serotonin Uptake Inhibitors
Therapeutics
Anxiety
Communication
Autism Spectrum Disorder
Pharmacology
Safety
Research
Population

Keywords

  • Adolescent
  • Antidepressant
  • Atypical antipsychotic
  • Autism
  • Children
  • Irritability
  • Mood stabilizer
  • Pediatric
  • Pharmacotherapy
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. / Stepanova, Ekaterina; Dowling, Susannah; Phelps, Molly; Findling, Robert L.

In: Dialogues in Clinical Neuroscience, Vol. 19, No. 4, 01.12.2017, p. 395-402.

Research output: Contribution to journalArticle

@article{0048ceed350640d58a59312f3877ea59,
title = "Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents",
abstract = "Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD. Though not FDA-approved, methylphenidate and guanfacine are effective for the management of hyperactivity in children with ASD. Selective serotonin reuptake inhibitors are often used in clinical practice to target anxiety and compulsions; however, there is little evidence to support its use in this population. There is a great need for further research on the safety and efficacy of existing psychotropic medications in youth with ASD, as well as the development of new treatment modalities for the core and associated behavioral symptoms.",
keywords = "Adolescent, Antidepressant, Atypical antipsychotic, Autism, Children, Irritability, Mood stabilizer, Pediatric, Pharmacotherapy, Treatment",
author = "Ekaterina Stepanova and Susannah Dowling and Molly Phelps and Findling, {Robert L}",
year = "2017",
month = "12",
day = "1",
language = "English (US)",
volume = "19",
pages = "395--402",
journal = "Dialogues in Clinical Neuroscience",
issn = "1294-8322",
publisher = "Servier International",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents

AU - Stepanova, Ekaterina

AU - Dowling, Susannah

AU - Phelps, Molly

AU - Findling, Robert L

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD. Though not FDA-approved, methylphenidate and guanfacine are effective for the management of hyperactivity in children with ASD. Selective serotonin reuptake inhibitors are often used in clinical practice to target anxiety and compulsions; however, there is little evidence to support its use in this population. There is a great need for further research on the safety and efficacy of existing psychotropic medications in youth with ASD, as well as the development of new treatment modalities for the core and associated behavioral symptoms.

AB - Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD. Though not FDA-approved, methylphenidate and guanfacine are effective for the management of hyperactivity in children with ASD. Selective serotonin reuptake inhibitors are often used in clinical practice to target anxiety and compulsions; however, there is little evidence to support its use in this population. There is a great need for further research on the safety and efficacy of existing psychotropic medications in youth with ASD, as well as the development of new treatment modalities for the core and associated behavioral symptoms.

KW - Adolescent

KW - Antidepressant

KW - Atypical antipsychotic

KW - Autism

KW - Children

KW - Irritability

KW - Mood stabilizer

KW - Pediatric

KW - Pharmacotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85041483140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041483140&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 395

EP - 402

JO - Dialogues in Clinical Neuroscience

JF - Dialogues in Clinical Neuroscience

SN - 1294-8322

IS - 4

ER -